PD-1/PD-L1 inhibitor

Phase 3Small molecule

SSecond Affiliated Hospital of Soochow University

PD-1/PD-L1 inhibitor is one of 90 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Biliary Tract CancerActive, not recruiting

Hepatocellular CarcinomaNot yet recruiting

Squamous Non-Small Cell Lung Cancer SqnsclcRecruiting

NSCLC (non-Small Cell Lung Cancer)Recruiting

IDH1 MutationRecruiting

Biliary Tract CancerPreclinical

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Not yet recruiting

Squamous Non-Small Cell Lung Cancer SqnsclcPhase 3

Recruiting

NSCLC (non-Small Cell Lung Cancer)Phase 3

Recruiting

IDH1 MutationPhase 2

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

PD-1/PD-L1 inhibitor

SSecond Affiliated Hospital of Soochow University

Phase 3

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

Doptelet

AAkarx

Preclinical

1 9

Vermox

WWim Janssens

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

IDH1 Mutation

NCT07282262

Q4 2027

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT07230314

Q4 2028

ApprovedRecruiting

NSCLC (non-Small Cell Lung Cancer)

NCT07754812

Q1 2029

Not yet recruiting

Biliary Tract Cancer

NCT07466238

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Suspended·TTongji Hospital··NCT04835025·200 enrolled

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT05603013·45 enrolled

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT06047860·30 enrolled

Advanced Refractory Solid Tumors1 trial

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT05790447·60 enrolled

Pneumonitis1 trial

Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

Completed·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology··NCT07036016·67,818 enrolled

Biliary Tract Cancer1 trial

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Not yet recruiting·PPeking University··NCT07466238·40 enrolled

Lung Cancer1 trial

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05735028·8 enrolled

4 more indications

Hepatocellular Carcinoma1 trial

Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib

Not yet recruiting·JJinling Hospital, China·Phase 2·NCT07230314·34 enrolled

IDH1 Mutation1 trial

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07282262·300 enrolled

NSCLC (Non-small Cell Lung Cancer)1 trial

A Multicenter, Open-Label, Single-Arm Phase I/II Study of Oral Paclitaxel Solution Combined With an Immune Checkpoint Inhibitor and Concurrent Stereotactic Body Radiotherapy as Neoadjuvant Treatment in Older Patients With Resectable Stage IIA-IIIB Non-Small Cell Lung Cancer

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Approved·NCT07754812·78 enrolled

Squamous Non-Small Cell Lung Cancer SqNSCLC1 trial

Efficacy and Safety of Metronomic Oral Paclitaxel Plus an Immune Checkpoint Inhibitor as Maintenance Therapy After First-Line Induction in Advanced Squamous Non-Small Cell Lung Cancer and Extensive-Stage Small Cell Lung Cancer: A Multicenter, Multi-Cohort Exploratory Study

Recruiting·AAnhui Provincial Cancer Hospital·Approved·NCT07744698·107 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for PD-1/PD-L1 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-1/PD-L1 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-1/PD-L1 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSecond Affiliated Hospital of Soochow University

PD-1/PD-L1 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Advanced Refractory Solid Tumors1 trial

Pneumonitis1 trial

Biliary Tract Cancer1 trial

Lung Cancer1 trial

Hepatocellular Carcinoma1 trial

IDH1 Mutation1 trial

NSCLC (Non-small Cell Lung Cancer)1 trial

Squamous Non-Small Cell Lung Cancer SqNSCLC1 trial

References

Drug Info

Quick Facts

Related News